EUVIMEDEUVIMED entdecken
Crossref

L26/P-231 AI-based insights into the developmental potential of oocytes from altruistic donors with polycystic ovaries or polycystic ovary syndrome

L. Weissheimer, S. Mattiello, R. Ternus, G. Andrade, L. Vanzella, E. MacKenzie, J. Fjeldstad, N. Frantz, M.I. Kulmann

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von L. Weissheimer und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Do oocytes from donors with polycystic ovary (PCO) morphology or polycystic ovary syndrome (PCOS) differ in developmental potential compared with those without these conditions? Summary answer Oocytes from donors with PCO or PCOS showed developmental potential comparable to controls, as assessed by AI-based image analysis and embryological outcomes. What is known already Careful selection of oocyte donors is essential to ensure high gamete quality and maximize IVF outcomes, especially in countries where donation is strictly voluntary and donor availability is limited. While some ovarian pathologies, such as endometriosis, are generally excluded from donation due to their association with poor quality oocytes and adverse outcomes, the suitability of donors with PCO or PCOS remains uncertain. Evidence regarding the impact of PCO/PCOS on the intrinsic developmental potential of oocytes is inconsistent, and emerging AI-based tools for oocyte assessment (MAGENTA™ which provides scores reflecting blastulation potential) may provide additional, objective insight into this debate. Study design, size, duration This single-center, retrospective, observational, cohort study included 1,101 donor oocytes obtained from 74 stimulation cycles performed between September 2024 and December 2025. Oocyte quality was assessed using MAGENTA™, to generate scores (0-10). PCO donors were diagnosed based on ultrasound examination, whereas PCOS donors presented oligo-anovulation and/or clinical/biochemical hyperandrogenism in addition to PCO morphology. A total of 48 oocyte donors were categorized into PCO/PCOS (31 cycles; 542 oocytes) and control groups (43 cycles; 559 oocytes). Participants/materials, setting, methods For MAGENTA™ evaluation, donor age and number of metaphase-II (MII) oocytes were collected, with high-resolution, two-dimensional images of fresh, denuded MII oocytes captured at 200× magnification, pre-vitrification or pre-ICSI accordingly, in frozen or fresh recipient cycles. Embryos were cultured to the blastocyst stage (Day5/6) and either transferred or vitrified according to clinical protocols. Embryological outcomes– fertilization,blastulation, top-quality blastocyst rates, and euploidy– were assessed in a subset of 407 inseminated oocytes across 49 recipient cycles. Main results and the role of chance Donor age was comparable between PCO/PCOS and control groups (30.4±2.6 vs. 30.6±3.2 years, p = 0.8174). As expected, PCO/PCOS donors exhibited a distinct ovarian profile compared to control donors, with significantly higher AMH levels (8.0±4.9 vs. 2.9±1.2 ng/mL, p < 0.0001), number of aspirated follicles (34.1±16.9 vs. 16.5±9.1, p = 0.0008), and number of retrieved MII oocytes (20.3±8.6 vs. 13.6±6.3, p = 0.0002). AI-based oocyte quality assessment (MAGENTA™ score) did not differ between PCO/PCOS and control oocytes (7.4±2.5 vs 6.9±2.5; p = 0.360). Subgroup analysis of oocytes from clinically confirmed PCOS donors (158 oocytes, 5 donors) also exhibited comparable AI-based quality scores (7.0±2.4, p = 0.320) compared to controls. In recipient cycles with known laboratory outcomes (407 oocytes, 49 cycles), fertilization (76.1% vs 73.8%, p = 0.587), blastocyst formation (53.1% vs 54.3%, p = 0.907), top-quality blastocyst rates (80.0% vs 88.4%, p = 0.738), and euploidy rates (59.1% vs 64.7%, p = 0.7526) were comparable between PCO/PCOS and control donor oocytes, respectively. Limitations, reasons for caution This retrospective, single-center study is subject to residual confounding. Donors with PCO and PCOS were grouped in most analysis, limiting subgroup-specific conclusions. Long-term pregnancy and neonatal outcomes were not assessed, and findings should be confirmed in prospective, multicenter studies. Wider implications of the findings These findings suggest that oocytes from donors with PCO/PCOS are not intrinsically compromised in developmental potential as measured by laboratory and clinical outcomes. AI-based oocyte assessment (MAGENTA™) may provide standardized, objective measures of oocyte quality, supporting evidence-based donor selection and expanding donor availability without adversely affecting embryological or genetic outcomes. Trial registration number No

Zitieren

APA

Weissheimer, L., Mattiello, S., Ternus, R., Andrade, G., Vanzella, L., MacKenzie, E., Fjeldstad, J., Frantz, N., & Kulmann, M. (2026). L26/P-231 AI-based insights into the developmental potential of oocytes from altruistic donors with polycystic ovaries or polycystic ovary syndrome. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.567

Vancouver

Weissheimer L, Mattiello S, Ternus R, Andrade G, Vanzella L, MacKenzie E, et al. L26/P-231 AI-based insights into the developmental potential of oocytes from altruistic donors with polycystic ovaries or polycystic ovary syndrome. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.567

BibTeX
@article{Weissheimer2026,
  author = {Weissheimer, L. and Mattiello, S. and Ternus, R. and Andrade, G. and Vanzella, L. and MacKenzie, E. and Fjeldstad, J. and Frantz, N. and Kulmann, M.I.},
  title = {L26/P-231 AI-based insights into the developmental potential of oocytes from altruistic donors with polycystic ovaries or polycystic ovary syndrome},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.567}
}
Kostenlos starten →